

This listing of claims will replace all prior versions, and listings, of claims in the application.

AMENDMENTS TO THE CLAIMS

1-33. (Canceled).

34. (Previously Presented) An antisense compound comprising a modified oligonucleotide consisting of about 13 to not more than 23 linked nucleosides targeted to a nucleic acid molecule encoding a p38 α mitogen-activated protein kinase, wherein said modified oligonucleotide comprises at least one modified sugar moiety or at least one modified nucleobase, wherein said modified oligonucleotide is complementary to at least an 8 contiguous nucleobase portion of nucleotides 1194 to 1277 of SEQ ID NO. 1, wherein said modified oligonucleotide specifically hybridizes to SEQ ID NO:1, and wherein the modified oligonucleotide does not comprise SEQ ID NO: 91, or 92.

35-41. (Canceled).

42. (Original) The antisense compound of claim 34 comprising a chimeric oligonucleotide.

43. (Previously Presented) The antisense compound of claim 34 which is a single-stranded or a double-stranded compound.

44-47. (Canceled).

48. (Original) The antisense compound of claim 34 comprising at least one modified internucleoside linkage.

49. (Original) The antisense compound of claim 48 wherein the modified internucleoside linkage is a phosphorothioate linkage.

50. (Original) The antisense compound of claim 34 comprising at least one modified sugar moiety.

51. (Previously Presented) The antisense compound of claim 50 wherein the modified sugar moiety is a 2'-O-methoxyethyl moiety or a 4'- $(CH_2)_n$ -O-2' bridge, wherein n is 1 or 2.

52. (Original) The antisense compound of claim 34 comprising at least one modified nucleobase.

53. (Original) The antisense compound of claim 52 wherein the modified nucleobase is a 5-methyl cytosine.

54-57. (Cancelled).

58. (Previously Presented) A pharmaceutical composition comprising the antisense compound of claim 34, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.

59-67. (Cancelled).

68. (Previously Presented) The antisense compound of claim 34, wherein the modified oligonucleotide comprises:

a gap segment consisting of linked deoxynucleosides;

a 5' wing segment consisting of linked nucleosides;

a 3' wing segment consisting of linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.

69. (Previously Presented) The antisense compound of claim 68, wherein the modified oligonucleotide comprises:

a gap segment consisting of eight to ten linked deoxynucleosides;

a 5' wing segment consisting of five to six linked nucleosides;

a 3' wing segment consisting of five to six linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment comprises a 2'-O-methoxyethyl sugar, wherein each cytosine in said modified oligonucleotide is a 5-methylcytosine, and wherein each internucleoside linkage of said modified oligonucleotide is a phosphorothioate linkage.

70. (Previously Presented) The antisense compound of claim 69, wherein the modified oligonucleotide consists of 20 linked nucleosides.

71.-82. (Cancelled)